Ambrosia ceases young blood plasma treatment


FDA says there is no proven clinical benefit of infusion of plasma from young donor.
Ambrosia has confirmed that it has ceased patient treatments.
Company had referred to its intravenous infusions of plasma as a medical treatment.
Ambrosia's trial was not performed under the Investigational New Drug (IND) program.
FDA concerned patients may be discouraged from seeking safe and effective treatments for serious illnesses.

Only 2 months after starting. Calling it a medical treatment may be contravened FDA guidance.
Read full article on CNN website
More Young Blood information, news and resources